Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Añadir filtros








Intervalo de año
1.
Braz. j. med. biol. res ; 52(11): e8772, 2019. graf
Artículo en Inglés | LILACS | ID: biblio-1039259

RESUMEN

This study aimed to investigate the mechanism of fluorofenidone (AKF-PD) in treating renal interstitial fibrosis in rats with unilateral urinary obstruction (UUO). Thirty-two male Sprague-Dawley rats were randomly divided into sham, UUO, UUO + enalapril, and UUO + AKF-PD groups. All rats, except sham, underwent left urethral obstruction surgery to establish the animal model. Rats were sacrificed 14 days after surgery, and serum was collected for renal function examination. Kidneys were collected to observe pathological changes. Immunohistochemistry was performed to assess collagen I (Col I) protein expression, and terminal deoxynucleotidyl transferase-mediated nick end-labeling staining to observe the apoptosis of renal tubular epithelial cells. The expression of Fas-associated death domain (FADD), apoptotic protease activating factor-1 (Apaf-1), and C/EBP homologous protein (CHOP) proteins was evaluated by immunohistochemistry and western blot analysis. AKF-PD showed no significant effect on renal function in UUO rats. The pathological changes were alleviated significantly after enalapril or AKF-PD treatment, but with no significant differences between the two groups. Col I protein was overexpressed in the UUO group, which was inhibited by both enalapril and AKF-PD. The number of apoptotic renal tubular epithelial cells was much higher in the UUO group, and AKF-PD significantly inhibited epithelial cells apoptosis. The expression of FADD, Apaf-1, and CHOP proteins was significantly upregulated in the UUO group and downregulated by enalapril and AKF-PD. In conclusion, AKF-PD improved renal interstitial fibrosis by inhibiting apoptosis of renal tubular epithelial cells in rats with UUO.


Asunto(s)
Animales , Masculino , Piridonas/farmacología , Obstrucción Ureteral/patología , Apoptosis/efectos de los fármacos , Células Epiteliales/efectos de los fármacos , Enfermedades Renales/patología , Piridonas/metabolismo , Nitrógeno de la Urea Sanguínea , Fibrosis , Inhibidores de la Enzima Convertidora de Angiotensina/metabolismo , Inhibidores de la Enzima Convertidora de Angiotensina/farmacología , Enalapril/metabolismo , Enalapril/farmacología , Distribución Aleatoria , Ratas Sprague-Dawley , Creatinina/sangre , Colágeno Tipo I/efectos de los fármacos , Colágeno Tipo I/metabolismo , Modelos Animales de Enfermedad , Factor de Transcripción CHOP/efectos de los fármacos , Factor Apoptótico 1 Activador de Proteasas/efectos de los fármacos , Factor Apoptótico 1 Activador de Proteasas/metabolismo , Proteína de Dominio de Muerte Asociada a Fas/efectos de los fármacos , Proteína de Dominio de Muerte Asociada a Fas/metabolismo
2.
Biol. Res ; 48: 1-10, 2015. graf, tab
Artículo en Inglés | LILACS | ID: biblio-950794

RESUMEN

BACKGROUND: Carbon tetrachloride (CCl4) induces hepatotoxicity in animal models, including the increased blood flow and cytokine accumulation that are characteristic of tissue inflammation. The present study investigates the hepato-protective effect of rutin on CCl4-induced hepatotoxicity in rats. RESULTS: Forty male Wistar rats were divided into four groups. Group I (control group) received 1 mL/kg of dimethyl sulfoxide intragastrically and 3 mL/kg olive oil intraperitoneally twice a week for 4 weeks. Group II received 70 mg/ kg rutin intragastrically. Groups III and IV received CCl4 (3 mL/kg, 30 % in olive oil) intraperitoneally twice a week for 4 weeks. Group IV received 70 mg/kg rutin intragastrically after 48 h of CCl4 treatment. Liver enzyme levels were determined in all studied groups. Expression of the following genes were monitored with real-time PCR: interleukin-6 (IL-6), dual-specificity protein kinase 5 (MEK5), Fas-associated death domain protein (FADD), epidermal growth factor (EGF), signal transducer and activator of transcription 3 (STAT3), Janus kinase (JAK), B-cell lymphoma 2 (Bcl2) and B-cell lymphoma-extra-large (Bcl-XL). The CCl4 groups showed significant increases in biochemical markers of hepatotoxicity and up-regulation of expression levels of IL-6, Bcl-XL, MEK5, FADD, EGF, STAT3 and JAK compared with the control group. However, CCl4 administration resulted in significant down-regulation of Bcl2 expression compared with the control group. Interestingly, rutin supplementation completely reversed the biochemical markers of hepatotoxicity and the gene expression alterations induced by CCl4. CONCLUSION: CCl4 administration causes alteration in expression of IL-6/STAT3 pathway genes, resulting in hepatotoxicity. Rutin protects against CCl4-induced hepatotoxicity by reversing these expression changes.


Asunto(s)
Animales , Masculino , Ratas , Rutina/farmacología , Transducción de Señal/efectos de los fármacos , Interleucina-6/metabolismo , Factor de Transcripción STAT3/metabolismo , Enfermedad Hepática Inducida por Sustancias y Drogas/tratamiento farmacológico , Aspartato Aminotransferasas/sangre , Tetracloruro de Carbono , Biomarcadores , Expresión Génica/efectos de los fármacos , Ratas Wistar , Proteínas Proto-Oncogénicas c-bcl-2/metabolismo , Sustancias Protectoras/farmacología , MAP Quinasa Quinasa 5/metabolismo , Alanina Transaminasa/sangre , Factor de Crecimiento Epidérmico/metabolismo , Proteína bcl-X/metabolismo , Quinasas Janus/metabolismo , Proteína de Dominio de Muerte Asociada a Fas/metabolismo , Reacción en Cadena en Tiempo Real de la Polimerasa , Hígado/efectos de los fármacos
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA